Bender Robert & Associates Buys New Position in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Bender Robert & Associates bought a new stake in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) during the 4th quarter, HoldingsChannel reports. The firm bought 11,590 shares of the company’s stock, valued at approximately $202,000.

Several other hedge funds have also modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its holdings in Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock worth $2,598,000 after purchasing an additional 1,092 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Pulse Biosciences during the 4th quarter worth approximately $193,000. Oppenheimer & Co. Inc. purchased a new stake in Pulse Biosciences during the 4th quarter worth approximately $311,000. Franklin Resources Inc. purchased a new stake in Pulse Biosciences during the 3rd quarter worth approximately $378,000. Finally, Barclays PLC increased its holdings in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Robert W. Duggan purchased 55,256 shares of the stock in a transaction dated Friday, December 13th. The stock was acquired at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 71.50% of the company’s stock.

Pulse Biosciences Stock Performance

PLSE stock opened at $17.14 on Wednesday. The stock’s 50 day moving average is $19.29 and its two-hundred day moving average is $18.33. Pulse Biosciences, Inc. has a 52-week low of $6.59 and a 52-week high of $25.00.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.